☆ 4.7 Article

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

LEUKEMIA (2020)

Journal

LEUKEMIA

Volume 34, Issue 4, Pages 963-965

Publisher

SPRINGERNATURE

DOI: 10.1038/s41375-020-0780-6

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML

Elisa Meddi, Arianna Savi, Federico Moretti, Flavia Mallegni, Raffaele Palmieri, Giovangiacinto Paterno, Elisa Buzzatti, Maria Ilaria Del Principe, Francesco Buccisano, Adriano Venditti, Luca Maurillo

Summary: In acute myeloid leukemia (AML), many patients experience relapse despite achieving complete remission. Traditional morphologic criteria are inadequate for assessing treatment response. Quantification of measurable residual disease (MRD) is a strong prognostic marker in AML, with MRD-negative patients having lower relapse rates and better survival. Different techniques for detecting MRD are available, and their use in guiding post-remission therapy is being actively investigated. Despite controversy, the prognostic value of MRD shows promise in supporting drug development and potentially expediting regulatory approval of new agents.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication

Ing S. Tiong, Sun Loo

Summary: Measurable residual disease (MRD) assessment plays an important role in prognostication and guiding treatment decisions in acute myeloid leukemia (AML). With the development of new therapeutics and the recent approval of NPM1 MRD as a regulatory endpoint, MRD-directed therapy and its potential application in clinical trials are being explored. This article reviews emerging molecular MRD markers, the impact of novel therapeutics on MRD endpoints, and the use of MRD as a predictive biomarker in guiding therapy in AML.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Hematology

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

H. Moses Murdock, Haesook T. Kim, Nathan Denlinger, Pankit Vachhani, Bryan Hambley, Bryan S. Manning, Shannon Gier, Christina Cho, Harrison K. Tsai, Shannon McCurdy, Vincent T. Ho, John Koreth, Robert J. Soiffer, Jerome Ritz, Martin P. Carroll, Sumithira Vasu, Miguel-Angel Perales, Eunice S. Wang, Lukasz P. Gondek, Steven Devine, Edwin P. Alyea, R. Coleman Lindsley, Christopher J. Gibson

Summary: Older patients with AML who undergo HCT have a high risk of relapse and poor survival. The outcomes of HCT in these patients are primarily driven by baseline genetic factors rather than mutations present in remission.

BLOOD (2022)

Add to Collection

Article Hematology

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Herve Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueno, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Dohner

Summary: Maintenance therapy with oral azacitidine improves overall survival and relapse-free survival in acute myeloid leukemia patients, regardless of their measurable residual disease (MRD) status at baseline.

BLOOD (2022)

Add to Collection

Article Oncology

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year

Riana van der Linde, Prudence N. Gatt, Sandy Smith, Marian A. Fernandez, Lachlin Vaughan, Emily Blyth, Jennifer Curnow, David A. Brown, Elizabeth Tegg, Sarah C. Sasson

Summary: This study found divergent utilities of flow cytometry-measurable residual disease (FC-MRD) in adult B-ALL and AML. FC-MRD was strongly associated with relapse and survival in AML but not in B-ALL. Additionally, there was a moderate correlation between FC-MRD and corresponding Mol-MRD in B-ALL, while no correlation was found in AML.

CANCERS (2023)

Add to Collection

Article Oncology

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Nikhil Patkar, Chinmayee Kakirde, Anam Fatima Shaikh, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Sitaram Ghoghale, Nilesh Deshpande, Dhanalaxmi Shetty, Syed Hasan Khizer, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Navin Khattry, Manju Sengar, Prashant Tembhare, Papagudi Subramanian, Sumeet Gujral

Summary: NGS-MRD is an effective tool for predicting relapse risk and prognosis in AML patients, particularly in those with intermediate cytogenetic risk and favorable cytogenetic risk. The kinetics of NGS-MRD clearance is crucial for patient survival. Combining NGS-MRD with FCM-MRD provides comprehensive information for better clinical management.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission

Madlen Jentzsch, Lara Bischof, Donata Backhaus, Dominic Brauer, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Summary: Allogeneic hematopoietic stem cell transplantation is a crucial treatment option for acute myeloid leukemia patients. The measurable residual disease status at transplantation, combined with the genetic risk at diagnosis, provides refined prognostic information.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission

Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?

Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Soo-Mee Bang, Jeong-Ok Lee

Summary: This study retrospectively examined the outcomes of 106 AML patients in CR1 undergoing AlloSCT with or without consolidation chemotherapy. Results showed that consolidation chemotherapy prior to AlloSCT with RIC conditioning did not negatively impact the outcomes, with longer RFS and overall survival in the consolidation group. Additionally, consolidation did not affect engraftment rates but may lead to a higher degree of chronic GVHD.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

Add to Collection

Article Oncology

Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

Jordi Esteve, Sebastian Giebel, Myriam Labopin, Tomasz Czerw, Depei Wu, Liisa Volin, Gerard Socie, Ibrahim Yakoub-Agha, Johan Maertens, Jan J. Cornelissen, Arnaud Pigneux, Avichai Shimoni, Rainer Schwerdtfeger, Helene Labussiere-Wallet, Nigel Russell, Anton Schattenberg, Patrice Chevallier, Vladimir Koza, Robin Foa, Christoph Schmid, Zinaida Peric, Mohamad Mohty, Arnon Nagler

Summary: This study analyzed the outcomes of patients with t(4;11) BCP-ALL treated with alloHSCT, finding that a negative MRD status pre-transplant was the strongest beneficial factor. Patients with t(4;11) BCP-ALL had inferior outcomes compared to those with NK BCP-ALL when MRD was detectable.

LEUKEMIA (2021)

Add to Collection

Article Oncology

ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms

Francesco Mannelli, Paola Guglielmelli, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Marco Vignetti, Sergio Amadori, Fabrizio Pane, Adriano Venditti, Alessandro M. Vannucchi

Summary: The evolution into a blast phase is a fatal event in myeloproliferative neoplasms, with a median survival of 3-6 months. Clinical trials with innovative approaches are needed for this category of patients. The ENABLE trial aims to test the combination of venetoclax and decitabine in patients with post-MPN blast phase, who have a poor prognosis.

FUTURE ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia

Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Roland Bruno Walter, Adriano Venditti, Francesco Buccisano

CANCERS (2023)

Add to Collection

Article Hematology

Fever of Unknown Origin and Multidrug-Resistant Organisms Colonization in AML Patients

Luca Guarnera, Gentiana Elena Trotta, Valentina Boldrini, Lucia Cardillo, Ilaria Cerroni, Valeria Mezzanotte, Gianmario Pasqualone, Arianna Savi, Beatrice Borsellino, Elisa Buzzatti, Raffaele Palmieri, Giovangiacinto Paterno, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

Summary: Colonization by multidrug-resistant organisms (MDRO) is a frequent complication in hematologic departments, which puts patients at risk of life-threatening bacterial sepsis. Fever of unknown origin (FUO) is a condition related to the delivery of chemotherapy in hematologic malignancies, in which the use of antibiotics is debated. The incidence, risk factors, and influence on the outcome of these conditions in patients with acute myeloid leukemia (AML) are not clearly defined.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2023)

Add to Collection

Letter Hematology

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic

Luca Guarnera, Elisa Buzzatti, Fabrizio Bonanni, Giovangiacinto Paterno, Antonella Riccitelli, Vittorio Forte, Adriano Venditti, Maria Ilaria Del Principe

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML

Elisa Meddi, Arianna Savi, Federico Moretti, Flavia Mallegni, Raffaele Palmieri, Giovangiacinto Paterno, Elisa Buzzatti, Maria Ilaria Del Principe, Francesco Buccisano, Adriano Venditti, Luca Maurillo

Summary: In acute myeloid leukemia (AML), many patients experience relapse despite achieving complete remission. Traditional morphologic criteria are inadequate for assessing treatment response. Quantification of measurable residual disease (MRD) is a strong prognostic marker in AML, with MRD-negative patients having lower relapse rates and better survival. Different techniques for detecting MRD are available, and their use in guiding post-remission therapy is being actively investigated. Despite controversy, the prognostic value of MRD shows promise in supporting drug development and potentially expediting regulatory approval of new agents.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients

Gianfranco Catalano, Alessandra Zaza, Cristina Banella, Elvira Pelosi, Germana Castelli, Elisabetta de Marinis, Ariela Smigliani, Serena Travaglini, Tiziana Ottone, Mariadomenica Divona, Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Emanuele Ammatuna, Ugo Testa, Clara Nervi, Adriano Venditti, Maria Teresa Voso, Nelida Ines Noguera

Summary: We characterized the metabolic background in different types of Acute Myeloid Leukemia (AML) by comparing the metabolism of primary AML blasts with that of normal hematopoietic progenitors. The AML blasts showed lower respiratory and glycolytic capacities compared to hematopoietic precursors. AML blasts can be grouped based on Proton Leak values, and the group with high Proton Leak and high respiratory capacity had shorter overall survival time and overexpression of MCL1 protein. MCL1 was found to directly bind to HK2 on the outer mitochondrial membrane, suggesting its role in inducing glycolysis and promoting resistance to therapy in AML cells.

LEUKEMIA (2023)

Add to Collection

Article Oncology

Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

L. Maurillo, A. Spagnoli, A. Candoni, C. Papayannidis, E. Borlenghi, D. Lazzarotto, L. Fianchi, M. Sciume, M. E. Zannier, F. Buccisano, M. I. Del Principe, V. Mancini, M. Breccia, R. Fanin, E. Todisco, M. Lunghi, R. Palmieri, N. Fracchiolla, P. Musto, G. Rossi, A. Venditti

Summary: This study compared the efficacy of azacitidine and decitabine in elderly patients with untreated AML. The results showed similar outcomes in terms of complete remission, overall survival, and disease free survival between the two groups.

LEUKEMIA RESEARCH (2023)

Add to Collection

Letter Medicine, General & Internal

Acute leukemia diagnosis during the COVID-19 pandemic

Luca Guarnera, Elisa Buzzatti, Francesco Marchesi, Daniele Armiento, Carla Mazzone, Saveria Capria, Emilia Scalzulli, Francesco Malfona, Sabina Chiaretti, Raffaele Palmieri, Giovangiacinto Paterno, Chiara Franzese, Fabrizio Bonanni, Arianna Savi, Gianmario Pasqualone, Federico Moretti, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

PANMINERVA MEDICA (2023)

Add to Collection

Review Hematology

Assessing eligibility for treatment in acute myeloid leukemia in 2023

Adriano Venditti, Roberto Cairoli, Morena Caira, Paola Finsinger, Fabio Finocchiaro, Benedetta Neri, Daniela De Benedittis, Giuseppe Rossi, Felicetto Ferrara

Summary: Age alone is no longer the sole indicator to determine eligibility for intensive chemotherapy in patients with acute myeloid leukemia (AML). The evaluation of comorbidities and overall performance status is also important in tailoring therapeutic options. Consensus criteria have been proposed to define eligibility for intensive and nonintensive chemotherapy in AML patients, and assessment of fitness is now essential in selecting the most appropriate treatment.

EXPERT REVIEW OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways

T. Ottone, G. Silvestrini, R. Piazza, S. Travaglini, C. Gurnari, F. Marchesi, A. M. Nardozza, E. Fabiani, E. Attardi, L. Guarnera, M. Divona, P. Ricci, M. A. Irno Consalvo, S. Ienzi, R. Arcese, A. Biagi, L. Fiori, M. Novello, A. Mauriello, A. Venditti, L. Anemona, M. T. Voso

Summary: By analyzing the transcriptome profile of AML patients, researchers found that TWIST1, ECM-receptor interaction, and focal-adhesion pathways were significantly deregulated. The study also showed that metformin can interfere with these processes.

LEUKEMIA (2023)

Add to Collection

Review Oncology

Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond

Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia, Giuseppe Sconocchia

Summary: The emergence of targeted therapies has revolutionized the management of B-lineage acute lymphoblastic leukemia, allowing for optimism in replacing traditional treatments. However, few patients currently benefit from these therapies, necessitating further research to improve outcomes, particularly in patients resistant to current treatments. This review discusses new therapeutic options, including bispecific antibodies, antibody-drug conjugates, and CAR-based therapies.

CANCERS (2023)

Add to Collection

Review Oncology

Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies-A Systematic Review

Maria Christina Cox, Fabiana Esposito, Massimiliano Postorino, Adriano Venditti, Arianna Di Napoli

Summary: This systematic review explores the clinical impact of serum paraprotein (PP) in low- and high-grade mature B-cell malignancies. The analysis shows that serum PP is consistently associated with high-risk biological and clinical features, as well as poor outcome. Screening for serum PP should be included in the diagnostic work-up of all mature B-cell malignancies.

CANCERS (2023)

Add to Collection

Letter Health Care Sciences & Services

Haematology and specialist palliative medicine education and training

Mario Luppi, Elena Bandieri, Adriano Venditti, Paolo Corradini

BMJ SUPPORTIVE & PALLIATIVE CARE (2023)

Add to Collection

Article Hematology

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti

Summary: The pivotal RATIFY study demonstrated that midostaurin combined with standard chemotherapy significantly reduced mortality in adult patients with newly diagnosed FLT3(mut) acute myeloid leukemia. This open-label, multicenter phase 3b trial aimed to further assess the safety and efficacy of midostaurin plus chemotherapy in different age groups. The results showed that the safety and efficacy of midostaurin remained consistent with previous findings regardless of age, sex, or induction regimen.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3trial

Michael Luebbert, Pierre W. Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J. F. M. Van der Velden, Richard Noppeney, Laimonas Griskevicius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foa, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus F. M. Posthuma, Mels Hoogendoorn, Anne Giraut, Marian Stevens-Kroef, Joop H. Jansen, Aniek O. de Graaf, Fabio Efficace, Emanuele Ammatuna, Jean-Pierre Vilque, Ralph Waesch, Heiko Becker, Nicole Blijlevens, Ulrich Duehrsen, Frederic Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls

Summary: This study compares the efficacy and safety of decitabine monotherapy with intensive chemotherapy in older patients with acute myeloid leukemia. The results show that 10-day decitabine monotherapy is as effective and safer than 3 + 7 chemotherapy in older patients.

LANCET HAEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.